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Abstract An active phosphatidylinositol 3-kinase (PI3K) has
been shown in nuclei of different cell types. The products of this
enzyme, i.e. inositides phosphorylated in the D3 position of the
inositol ring, may act as second messengers themselves. Nuclear
PI3K translocation has been demonstrated to be related to an
analogous translocation of a PtdIns(3,4,5)P3 activated PKC, the
j isozyme. We have examined the issue of whether or not in the
osteoblast-like clonal cell line MC3T3-E1 there may be observed
an insulin-like growth factor-I- (IGF-I) and platelet-derived
growth factor- (PDGF) dependent nuclear translocation of an
active Akt/PKB. Western blot analysis showed a maximal
nuclear translocation after 20 min of IGF-I stimulation or after
30 min of PDGF treatment. Both growth factors increased
rapidly and transiently the enzyme activity of immunoprecipi-
table nuclear Akt/PKB on a similar time scale and after 60 min
the values were slightly higher than the basal levels. Enzyme
translocation was blocked by the specific PI3K inhibitor,
LY294002, as well as cell entry into S-phase. Confocal
microscopy showed an evident increase in immunostaining
intensity in the nuclear interior after growth factor treatment
but no changes in the subcellular distribution of Akt/PKB when a
LY294002 pre-treatment was administered to the cells. These
findings strongly suggest that the intranuclear translocation of
Akt/PKB is an important step in signalling pathways that
mediate cell proliferation. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Akt/PKB is a 57 kDa serine/theronine kinase that shares
sequence homology with both PKC and PKA [1]. Akt/PKB
has been recognized to be the product of c-Akt, the cellular
homologue of the viral oncogene v-Akt [2]. Molecular analysis
revealed the existence in Akt/PKB of a pleckstrin homology
domain, located at the amino-terminus of the kinase, which
mediates interaction of Akt/PKB with other cell proteins [3].
Several growth factors including insulin, PDGF, EGF,
FGF and IGF-I are capable of activating Akt/PKB [4]. Akt/
PKB is a downstream target of PI3K, as demonstrated by
experiments in which PI3K was inhibited either by Wortman-
nin or LY294002, or by overexpression of a deletion mutant
of the regulatory subunit of PI3K [5^7]. It is commonly
thought that Akt/PKB is activated following its recruitment
to the plasma membrane. This activation requires phosphor-
ylation of threonine and serine residues of Akt/PKB, a reac-
tion which is catalyzed by PDK1 and by a still unidenti¢ed
PDK2, respectively. In addition PDK1 has been demonstrated
to be active only in the presence of PtdIns(3,4,5)P3, the ¢nal
product of PI3K [8,9].
In addition to its well established role at the plasma mem-
brane, it is now widely accepted that PI3K is also involved in
nuclear signal transduction events (for a comprehensive re-
view see [10]). The generation at the nuclear level of lipid
messenger molecules, such as DAG or PtdIns(3,4,5)P3, has
been demonstrated to be the driving force to recruit to the
nuclear compartment PKC K in Swiss 3T3 cells or PKC j in
HL-60 and PC12 cells, respectively [11^13]. In the latter case
the translocation of PKC j followed a progressive and sus-
tained nuclear translocation of PI3K. This PI3K nuclear
translocation has mainly been linked to cell di¡erentiation
[12,13].
In addition there are some reports in the literature that
have described an intranuclear migration of Akt/PKB follow-
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ing serum stimulation of starved human ¢broblasts or trigger-
ing the B cell antigen receptor (BCR) in B lymphocytes
[14,15].
In light of these ¢ndings we decided to investigate whether
or not Akt/PKB translocates to the nucleus of MC3T3-E1
cells in response to stimulatory growth factors such as IGF-
I or PDGF and if this event is dependent on PI3K activity.
Here, we show that both of these growth factors are capable
of promoting a nuclear migration of Akt/PKB and this event
is blocked by a selective PI3K inhibitor, LY294002.
2. Materials and methods
2.1. Materials
D-MEM, FCS, monoclonal antibody to L-tubulin, normal rabbit
IgG, NGS, Cy3-conjugated anti-rabbit IgG, peroxidase-conjugated
anti-rabbit IgG, and BSA were from Sigma, St. Louis, MO, USA.
IGF-I, PDGF (B/B), histone H2B, and the Lumi-LightPlus enhanced
chemiluminescence detection kit were from Roche Molecular Bio-
chemicals, Milan, Italy. Protein A-agarose was purchased from Trans-
duction Laboratories, Lexington, KY, USA. [Q-32P]ATP was from
Amersham Pharmacia Biotech, Uppsala, Sweden. LY294002 was
from Calbiochem, La Jolla, CA, USA. The Protein Assay kit (deter-
gent compatible) was from Bio-Rad, Hercules, CA, USA. cAMP-de-
pendent protein kinase inhibitor peptide was from Bachem (Buben-
dorf, Switzerland). P-81 paper was from Whatman (Maidstone, UK).
2.2. Cell culture
MC3T3-E1 mouse calvaria ¢broblasts were cultured in D-MEM
containing 10% FCS. Prior to stimulation, cells, seeded at 3U103/
cm2, were subcultured for 24 h and then cultured for an additional
36 h in serum-free medium containing 0.5% BSA. Quiescent cultures
were washed twice with serum-free medium containing 0.2% BSA,
then incubated in the same medium for the indicated times in the
presence of 30 ng/ml of either IGF-I or PDGF. For treatment with
LY294002, the drug was added at 25 WM to serum-free medium for 1 h
prior to stimulation with growth factors.
For 5-BrdU incorporation, to detect cells in S-phase, cells were
labelled with 100 WM 5-BrdU for 10 min and treated as previously
described [16].
2.3. Isolation of nuclei
This was accomplished as previously reported, with minor changes
[17]. Brie£y, cells (5U106) were resuspended in 500 Wl of 10 mM Tris^
HCl, pH 7.8, 1% Nonidet P-40, 10 mM L-mercaptoethanol, 0.5 mM
phenylmethyl £uoride (PMSF), 10 Wg/ml soybean trypsin inhibitor,
1 Wg/ml of leupeptin and aprotinin, 1.0 mM Na3VO4, 20 mM okadaic
acid. They were incubated at 0‡C for 2 min, then 500 Wl of double-
distilled H2O was added and the cells allowed to swell for 2 min. Cells
were sheared by eight passages through a 22-gauge needle. Nuclei
were recovered by centrifugation at 400Ug for 6 min and washed
once in 10 mM Tris^HCl, pH 7.4, 2 mM MgCl2, plus protease and
phosphatase inhibitors as above. The purity of nuclear preparations
was evaluated by Western blot analysis using a monoclonal antibody
to L-tubulin, as previously described [18]. The absence of immunore-
activity to the cytoskeletal protein in the isolated nuclear preparations
con¢rmed that the isolation procedure produced nuclei of high purity
that were free of cytoplasmic contaminants (data not shown).
2.4. Preparation of whole cell homogenates and cytosolic extracts
To obtain homogenates, cells were resuspended in 50 mM Tris^
HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 1% Triton
X-100, 0.5 mM PMSF, 10 Wg/ml soybean trypsin inhibitor, 1 Wg/ml of
leupeptin and aprotinin, 1.0 mM Na3VO4, 20 mM okadaic acid, and
homogenized by 30 passages through a 25-gauge needle.
2.5. Protein assay
This was performed according to the instruction of the manufac-
turer using the Bio-Rad Protein Assay (detergent compatible).
2.6. Western blot analysis
Proteins (from 3U106 nuclei) separated on 7.5% polyacrylamide
gels were transferred to nitrocellulose sheets using a semi-dry blotting
apparatus. Sheets were saturated in PBS containing 5% normal goat
serum and 4% BSA for 60 min at 37‡C (blocking bu¡er), then incu-
bated overnight at 4‡C in blocking bu¡er containing a polyclonal
antibody diluted 1:8000, directed to the C-terminus region of Akt1
and Akt2 (PKB K and L) [7]. After four washes in PBS containing
0.1% Tween-20, they were incubated for 30 min at room temperature
with peroxidase-conjugated anti-rabbit IgG, diluted 1:3000 in PBS^
Tween-20, and washed as above. Bands were visualized by the en-
hanced chemiluminescence method. Densitometric analysis was per-
formed on the Molecular Analyst GS670 (Bio-Rad, Hercules, CA,
USA).
2.7. Immunoprecipitation of Akt/PKB
Nuclei (from 5U106 cells) were lysed for 30 min at 4‡C in 50 mM
HEPES, pH 7.9, 100 mM NaCl, 10% glycerol, 10 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.0 mM Na3VO4, 1 mM PMSF, 1 Wg/ml
leupeptin and aprotinin. The suspension was passed several times
through a 26-gauge needle, then centrifuged at 12 000Ug for 15 min
at 4‡C. Lysates (1 ml, containing 500 Wg of protein) were pre-cleared
by adding 5 Wg of normal rabbit IgG and 10 Wg of 50% protein A-
agarose, followed by incubation for 1 h at 4‡C and centrifugation at
12 000Ug for 10 min at 4‡C. Cell lysates were incubated for 2 h at 4‡C
under constant agitation with 5 Wg of a polyclonal antibody to Akt/
PKB. 10 Wg of 50% protein A-agarose was added and incubation
proceeded for 1 h at 4‡C under constant agitation.
2.8. Akt/PKB activity assay
The immunoprecipitates were washed twice in lysis bu¡er, once in
distilled water and twice in the Akt/PKB kinase bu¡er (20 mM
HEPES^NaOH, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM
DTT) as previously reported [19]. Assays (100 Wl) contained 20 mM
HEPES^NaOH, pH 7.4, 10 mM MgCl2, 10 mM MnCl2, 1 mM DTT,
1 WM cAMP-dependent protein kinase inhibitor peptide, 5 Wg histone
H2B as exogenous substrate, 2 WM ATP, 10 WCi [Q-32P]ATP (3000 Ci/
mmole). Samples were incubated for 30 min at 30‡C and the reaction
was then stopped by spotting 80 Wl onto P-81 ¢lter papers and im-
mersing in 1% (v/v) orthophosphoric acid. The papers were washed
several times, rinsed in ethanol, and air-dried, and the radioactivity
was determined by scintillation counting. Background values, ob-
tained by samples in which the anti-Akt/PKB antibody was replaced
by normal rabbit serum, were subtracted from all values.
2.9. In situ immuno£uorescence
Cultures of MC3T3-E1 cells (control and growth factor-treated),
grown on glass coverslips, were washed twice in cold PBS, pH 7.2,
¢xed with freshly prepared 4% paraformaldehyde (30 min at room
temperature) and permeabilized with 0.2% Triton X-100 in PBS (10
min). Samples were reacted with the polyclonal antibody (diluted
1:500) directed against Akt/PKB and used also for Western blotting
and immunoprecipitates [7]. The pictures presented in this article have
been obtained by means of the monoclonal antibody. The anti-Akt/
PKB antibodies were diluted in 2% BSA, 3% NGS in PBS. The sec-
ondary antibody was either a Cy3-conjugated anti-rabbit or anti-
mouse IgG, diluted 1:1000. All incubations were carried out at
37‡C. Samples were subsequently washed three times in PBS and
mounted as previously described [20]. Confocal laser scanning micro-
scope (CLSM) and image processing analysis were performed as de-
scribed previously [21]. The quantitative analysis of £uorescence in-
tensity was carried out on confocal as reported elsewhere [22,23].
2.10. Statistical analysis
Data are the means from three di¡erent experiments and are ex-
pressed as mean þ S.D. The asterisk indicates signi¢cant di¡erences
(P6 0.01) in a Student’s paired t-test. All of the other di¡erences
were found to be not signi¢cant with Ps 0.01.
3. Results
3.1. IGF-I and PDGF induce nuclear translocation of an active
Akt/PKB
Nuclei prepared from quiescent cells showed by means of
Western blotting the constitutive presence of Akt/PKB, which
migrated at 57 kDa. IGF-I treatment of MC3T3-E1 cells in-
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duced an increase in intranuclear amount of Akt/PKB, which
was maximal after 20 min of stimulation (Fig. 1). At 60 min
of treatment nuclear Akt/PKB protein was still higher than at
time 0, as evidentiated also by densitometric analysis of West-
ern blots (Fig. 1 and Table 1). At variance, maximal nuclear
translocation of Akt/PKB in PDGF-treated samples occurred
at 30 min. Also in this case, at 60 min since the beginning of
stimulation we observed a decrease in immunochemical reac-
tivity that, however, remained at a level higher than the con-
trol (Fig. 1 and Table 1). In both cases, pre-treatment for 1 h
of cells with a PI3K-speci¢c pharmacological inhibitor,
LY294002 (25 WM), suppressed the growth factor-dependent
nuclear translocation of Akt/PKB in MC3T3-E1 osteoblast
cells (Fig. 1 and Table 1). In contrast, no marked changes
in the amount of Akt/PKB protein were detected in whole
cell homogenates (Fig. 1).
Changes in nuclear Akt/PKB activity were measured by
means of immunoprecipitation of the enzyme followed by in
vitro phosphorylation of exogenous histone H2B. Exposure to
IGF-I resulted in a rapid increase (nearly 5-fold) in nuclear
Akt/PKB activity, that reached its peak at 20 min of treat-
ment (Fig. 2). Starting from this time point, it was observed a
slow and progressive decrease of the enzymatic activity, that
at 60 min after stimulation was about 2-fold above basal
activity.
On the other hand, the increase in nuclear Akt/PKB activity
induced by PDGF rose in a more regular manner, with the
highest activity at 30 min (Fig. 2). Also in this case, the max-
imal activity resulted in an about 5-fold rise. Afterwards, a
decrease similar to that observed for IGF-I-treated samples
was detected (Fig. 2).
If the cells had been exposed to LY294002 for 1 h prior to
stimulation with growth factors, no increase in nuclear Akt/
PKB activity was measured in immunoprecipitates derived
from cells treated with either IGF-I or PDGF.
In parallel we wanted to assay if the nuclear recruitment of
an active Akt/PKB could be related to the capacity of IGF-I
or PDGF to induce S-phase entry in serum starved osteo-
blasts. As shown in Table 2, prior to mitogenic stimulation
Fig. 1. IGF-I and PDGF induce nuclear translocation of Akt/PKB
in MC3T3-E1. Western blotting analysis showing the presence of
Akt/PKB in whole cells and isolated nuclei. 80 Wg of nuclear protein
was blotted to each lane, and the blots were also normalized to an
endogenous nuclear protein (lamin B). Lane 1, unstimulated cells ;
lane 2, samples from cells exposed to IGF-I alone for 20 min; lane
3, samples from cells exposed to IGF-I alone for 60 min; lane 4,
samples from cells exposed to IGF-I plus LY294002 for 20 min;
lane 5, samples from cells exposed to PDGF alone for 30 min; lane
6, samples from cells exposed to PDGF alone for 60 min; lane 7,
samples from cells exposed to PDGF plus LY294002 for 30 min.
Table 1
Densitometric analysis of Western blots showing intranuclear translocation of Akt/PKB
Agonist 0 min (control) 20 min 30 min 60 min 20 min+LY294002 30 min+LY294002
None 12 þ 2.4 ^ ^ ^ ^
IGF-I ^ 43.1 þ 4.7* ^ 20 þ 3.2* 10 þ 2.3 ^
PDGF ^ ^ 39 þ 4.3* 23 þ 3.7* ^ 11 þ 2.5
Nuclear protein (80 Wg) from quiescent cells, or cells stimulated for various times with IGF-I or PDGF (either in the presence or in the absence
of LY294002) was separated by polyacrylamide gel electrophoresis and blotted to nitrocellulose paper. Blots were probed with a polyclonal
antibody to PI3K which was then revealed by enhanced chemiluminescence. Films were scanned with a Molecular Analyst GS670. Data are ex-
pressed as arbitrary units. Asterisks indicate values that are signi¢cantly di¡erent (P6 0.01) from control.
Fig. 2. Exposure of MC3T3-E1 cells to either IGF-I or PDGF in-
creases immunoprecipitable nuclear Akt/PKB activity. Black bars:
cells treated with either IGF-I or PDGF. Hatched bars: cells treated
with either of the two growth factors plus LY294002. Basal levels
measured in the presence or in the absence of LY294002 were
954 þ 123 dpm and 829 þ 133 dpm, respectively. Results are the
means of three separate experiments. Standerd deviation is shown.
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almost all cells were quiescent. Treatment with either IGF-I or
PDGF was able to induce DNA synthesis that starting from
12 h after growth factor administration increased progres-
sively toward 20 h of treatment. Interestingly, pre-treatment
of cells with LY294002 blocked DNA synthesis, that remained
at control levels at all the examined times.
3.2. Subcellular redistribution of AKT/PKB after IGF-I and
PDGF stimulation
CLSM analysis of control cells immunostained with anti-
Akt/PKB antibody showed the enzyme to be predominantly
located in the cytoplasm. Nevertheless, nuclei, identi¢ed by
means of phase-contrast microscopy (data not shown),
Fig. 3. CLSM analysis of Akt/PKB distribution in MC3T3-E1 cells. A: Unstimulated cells. B: Unstimulated cells pre-treated with LY294002
(25 WM) for 1 h. C: Cells stimulated with IGF-I for 10 min. D: Cells stimulated with PDGF for 20 min. E: Cells stimulated with IGF-I for
20 min. F: Cells stimulated with PDGF for 30 min. G: Cells stimulated with IGF-I for 60 min. H: Cells stimulated with PDGF for 60 min. I :
Cells pre-treated with LY294002 and then exposed to IGF-I for 20 min. J: Cells pre-treated with LY294002 and then exposed to PDGF for 30
min. Scale bar: 5 Wm.
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showed also in control cells the presence of some immuno-
staining, in agreement with both Western blotting analysis
and enzymatic assays (Fig. 3A). Pre-treatment of cells with
LY294002 did not in£uence the subcellular distribution of
Akt/PKB (Fig. 3B). After 10 min of IGF-I stimulation, we
detected in both the plasma membrane and the nuclear inte-
rior an evident increase in immunostaining intensity (Fig. 3C).
Similar results were obtained with PDGF-treated samples, but
after 20 min of stimulation (Fig. 3D). Maximal intranuclear
translocation in IGF-I-exposed samples was observed after 20
min. The nuclear £uorescent pattern was characterized by a
very brilliant ¢brogranular distribution (Fig. 3E). In the case
of PDGF stimulation, the nuclear interior was immunostained
with a brilliant £uorescence after 30 min of exposure (Fig.
3F).
60 min after the beginning of stimulation with either IGF-I
or PDGF, Akt/PKB immunoreactivity was again dispersed
throughout the cytoplasm while intranuclear positivity was
still higher than in control cells (Fig. 3G and H). Cells pre-
treated with 25 WM LY294002 and then exposed to either
IGF-I or PDGF up to 20 or 30 min, respectively, did not
show any intranuclear migration or subcellular modi¢cation
of Akt/PKB (Fig. 3I and J).
CLSM quantitative evaluation of Akt/PKB nuclear trans-
location (Table 3) in MC3T3-E1 cells gave results in agree-
ment with activity assays and Western blots, indicating a peak
of nuclear £uorescence after 20 or 30 min of IGF-I or PDGF
treatment respectively.
The percentage of cells exhibiting the nuclear translocation
of Akt/PKB in response to growth factors shows that in both
cases nearly 60% of the cells responded to growth factors with
a nuclear translocation of the enzyme (Table 4).
4. Discussion
In this study we have employed several techniques to follow
the intranuclear localization of Akt/PKB during growth factor
stimulation of MC3T3-E1 osteoblasts. Akt/PKB is present in
the nucleus of these cells also when they are quiescent and in
response to stimulation with either IGF-I or PDGF, there is a
striking increase in the amount of intranuclear Akt/PKB. This
increase occurs more rapidly in the case of IGF-I in compar-
ison with PDGF. The enhanced intranuclear amount of Akt/
PKB is paralleled by an increase of its enzymatic activity.
Activation of Akt/PKB has previously mainly been linked
to growth factor-induced events occurring at the plasma mem-
brane level [24], in a PI3K-dependent membrane translocation
step that requires the phosphorylation of the protein at T308
and S473 [3].
Intranuclear presence of Akt/PKB was ¢rst reported in
PC12 cells [25]. Subsequently several stimuli have been shown
to be capable of inducing intranuclear migration of Akt/PKB,
such as serum, okadaic acid and IGF-I [14,26]. It should be
underscored however that this study demonstrating IGF-I
nuclear translocation of Akt/PKB was carried out in human
embryonic kidney cells overexpressing the human L isoform of
Akt/PKB. We used a polyclonal antibody directed against the
C-terminus region of PKB K and L (Akt1 and Akt2) [7]. Even
if PKB Q has a truncated form of C-terminus region, the three
isoforms display a high homology and similarity in function
[1], and the observed translocation could be considered highly
representative of Akt/PKB behavior. In this report we have
con¢rmed the capability of IGF-I to induce the nuclear mi-
gration of Akt/PKB, but we have employed a di¡erent line
and moreover we have investigated the behavior of the endog-
enous protein. Furthermore we have identi¢ed PDGF as an
additional growth factor which promotes the intranuclear mi-
gration of Akt/PKB.
Very recently it has been reported a possible mechanism
regarding the nuclear translocation of Akt1. It has been de-
scribed that the TCL1 oncogene, involved in the development
of human mature T-cell leukemia, participates in PI3K-depen-
dent Akt1 signalling pathway by enhancing Akt1 kinase ac-
tivity and mediating, through a cytoplasmic interaction, Akt1
nuclear translocation [27].
Akt/PKB is known to be regulated by PI3K products [6]. In
MC3T3-E1 cells, induced by the same stimuli, we have de-
tected an intranuclear translocation also of an active PI3K,
that on a time scale precedes migration to the nucleus of an
active Akt/PKB [28].
Concerning PI3K, its intranuclear accumulation is depen-
Table 2
Percent distribution of S-phase cells in MC3T3-E1 cells after stimu-
lation with either IGF-I or PDGF
Cell treatment Percentage of 5-BrdU positive cells
(time from treatment)
12 h 16 h 20 h
Serum starved 2.7 þ 2.1 2.5 þ 1.9 2.2 þ 1.8
IGF-I 20 h 8.7 þ 1.9 14.5 þ 2.0 18.7 þ 2.4
IGF-I+LY294002 2.8 þ 1.5 2.9 þ 1.8 3.4 þ 1.6
PDGF 16.9 þ 2.2 27.4 þ 2.9 32.1 þ 3.0
PDGF+LY294002 3.1 þ 1.4 4.4 þ 1.7 4.6 þ 1.9
MC3T3-E1 mouse calvaria ¢broblasts were cultured in D-MEM
containing 10% fetal calf serum. Prior to stimulation, cells, seeded
at 3U103/cm2, were subcultured for 24 h and then cultured for an
additional 36 h in serum-free medium containing 0.5% BSA. Quies-
cent cultures were washed twice with serum-free medium containing
0.2% BSA, then incubated in the same medium for the indicated
times in the presence of 30 ng/ml of either IGF-I or PDGF. For
evaluation of S-phase cells, osteoblast were labelled with 100 WM 5-
BrdU for 10 min. The results are the means from three di¡erent ex-
periments þ S.D. Asterisks indicate values that are signi¢cantly dif-
ferent (P6 0.01) from control.
Table 3
Quantitative analysis by CLSM of the amount of nuclear Akt/PKB in MC3T3-E1 cells in response to either IGF-I or PDGF
Condition 10 min 20 min 30 min 60 min
IGF-I 103 þ 11* 235 þ 19* 201 þ 14* 64 þ 8
IGF-I+LY294002 50 þ 5 48 þ 7 52 þ 5 53 þ 4
PDGF 82 þ 7 156 þ 14* 220 þ 17* 88 þ 9
PDGF+LY294002 46 þ 6 49 þ 7 51 þ 5 49 þ 6
Growth factors were applied for the indicated times. Results are expressed as arbitrary £uorescence units. Basal levels measured in the absence
or in the presence of LY294002 were 45 þ 6 and 41 þ 5, respectively. Asterisks indicate values that are signi¢cantly di¡erent (P6 0.01) from con-
trol.
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dent on its enzymatic activity. In fact, pre-treatment of
MC3T3-E1 cells with LY294002 abolished intranuclear trans-
location of PI3K, as also demonstrated in SaoS-2 cells [23] or
in HL-60 cells [12,29]. Because intranuclear Akt/PKB is ac-
tive, it must be phosphorylated on threonine and serine resi-
dues. The phosphorylation on Thr-308 is catalyzed by PDK1.
Since so far intranuclear migration of PDK1 has been ruled
out [30], it is currently thought that Akt/PKB could be acti-
vated in the cytoplasm and then it migrates to the nucleus
[15]. However we cannot exclude the possibility that for sus-
tained intranuclear permanence and activation of Akt/PKB,
as induced by IGF-I or PDGF, there is also the need for the
presence of an active PI3K within the nuclear compartment.
In addition nuclear Akt/PKB activity appears to be important
for S-phase entry of the cells. Akt/PKB may be, at the nuclear
level, one of the transducers of the PI3K activity required for
progression through G1-phase of PDGF-treated ¢broblasts
[31].
Activated nuclear Akt/PKB is involved in several functions
such as the phosphorylation of the winged helix transcription
factor FKHR1 (which is induced by IGF-I, see for example
[32,33]) and the phosphorylation of the Forkhead transcrip-
tion factor AFX [34].
Our knowledge of lipid second messenger signalling path-
way has strikingly advanced recently due to the recognition
that Akt/PKB is one of the major targets of tyrosine kinase
receptor-stimulated lipid kinases. The results presented in this
paper strengthen the contention that Akt/PKB besides the
roles it plays at the plasma membrane is involved in trans-
ducing key signals to the nucleus, such as proliferative stimuli.
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Table 4
Percentage of cells showing nuclear translocation of Akt/PKB
Cell treatment 10 min 20 min 30 min
IGF-I 25 þ 4* 61 þ 8* 52 þ 7*
IGF-I+LY294002 5 þ 2 8 þ 1 6 þ 2
PDGF 17 þ 3* 39 þ 6* 57 þ 6*
PDGF+LY294002 6 þ 1 5 þ 3 8 þ 2
Quiescent cell values were 3 þ 2. For each experiment 200 cells were
counted. The data are the means þ S.D. from three separate experi-
ments. Asterisks indicate values that are signi¢cantly di¡erent
(P6 0.01) from control.
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